For citations:
Vinogradova O.Yu., Pankraskina M.M., Neverova A.L., Shikhbabaeva D.I., Murzabekova M.A., Chernikov M.V., Popova A.V., Kosenkova V.P., Egoryan L.B., Ptushkin V.V. Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study. Oncohematology. 2024;19(3):16-33. (In Russ.) https://doi.org/10.17650/1818-8346-2024-19-3-16-33